Observational study / 2015
Glucosamine and chondroitin use was not linked to symptom relief or reduced disease progression in patients with knee osteoarthritis.
Researchers analyzed 4-year follow-up data from 1,625 patients with knee osteoarthritis from the Osteoarthritis Initiative using a new-user design and marginal structural models. During follow-up, 18% of participants initiated treatment. Compared to never-users, users of glucosamine/chondroitin at all assessments showed no clinically significant differences in WOMAC pain (β = 0.68 [95% CI -0.16 to 1.53]), WOMAC stiffness (β = 0.41 [95% CI 0 to 0.82]), WOMAC function (β = 1.28 [95% CI -1.23 to 3.79]), or joint space width (β = 0.11 [95% CI -0.21 to 0.44]).
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study using marginal structural models
- Who was studied
- 1,625 participants with knee osteoarthritis from the Osteoarthritis Initiative not using glucosamine/chondroitin at baseline
- What was measured
- WOMAC pain, stiffness, and function, and joint space width (JSW)
THE PAPER
Effects of glucosamine and chondroitin supplementation on knee osteoarthritis: an analysis with marginal structural models.
Yang S, Eaton CB, McAlindon TE, Lapane KL. Arthritis Rheumatol, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.